Nexalin Technology, Inc. (NASDAQ: NXL) announced that two clinical abstracts evaluating its DIFS™ 15 mA, 77.5 Hz treatment platform have been accepted for presentation at the 2026 NYC Neuromodulation Conference, according to a company statement.

The abstracts are based on data from an 8-week, single-center, prospective pilot trial conducted at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo. Adults diagnosed with generalized anxiety disorder and comorbid insomnia received 20 sessions of the company's 15 mA deep-brain frequency stimulation over four weeks, followed by a four-week follow-up period. Each 40-minute session used the Nexalin DIFS™ device at 15 mA and 77.5 Hz.

Key data points from the accepted abstracts include an anxiety response rate of 77.8% at Session 20, and a decrease of 14.73 points on the Hamilton Anxiety Rating Scale by Session 5. By Session 20, HAM-A scores had decreased by 18.30 points, with reductions observed at the 8-week post-treatment follow-up. Hamilton Depression Rating Scale scores decreased by 9.90 points by Session 20, with both response and remission rates reaching 66.7%. Pittsburgh Sleep Quality Index scores improved at end of treatment and remained improved at the 8-week follow-up. No serious adverse events, seizures, or manic or hypomanic switches were reported.

The two accepted abstracts are titled "Transcranial Alternating Current Stimulation for the Treatment of Anxiety: Preliminary Results from an Open-Label Pilot Clinical Trial" and "Transcranial Alternating Current Stimulation for Comorbid Anxiety and Insomnia: Preliminary Findings on Insomnia and Quality of Life from an Open-Label Pilot Trial."

The trial was conducted in Brazil, where the company states it is preparing for a potential product launch. Nexalin's Gen-2 15 milliamp device has received approval in China, Brazil, Oman, and Israel. The company is also pursuing an FDA De Novo regulatory pathway in the United States.

The results are preliminary and drawn from an open-label, single-center pilot study without a placebo control group.